Perfusion and metabolism imaging studies in Parkinson's disease.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Danish Medical Journal

• Publication date

  2012-06-01

• Fields of study

  Medicine

• Identifiers
  PMID 22677251
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glucose metabolism in small subcortical structures in Parkinson’s disease

  2012cited by this paper
• The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status

  2011cited by this paper
• Cerebral blood flow by arterial spin labeling in poststroke dementia

  2011cited by this paper
• Ventricular enlargement and mild cognitive impairment in early Parkinson's disease

  2011cited by this paper
• Abnormal metabolic brain networks in Tourette syndrome

  2011cited by this paper
• Focal cortical and subcortical atrophy in early Parkinson's disease

  2011cited by this paper
• Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease.

  2011cited by this paper
• FDG PET in the Evaluation of Parkinson's Disease.

  2010cited by this paper
• Detection by voxel-wise statistical analysis of significant changes in regional cerebral glucose uptake in an APP/PS1 transgenic mouse model of Alzheimer's disease

  2010cited by this paper
• Interindividual Variations of Cerebral Blood Flow, Oxygen Delivery, and Metabolism in Relation to Hemoglobin Concentration Measured by Positron Emission Tomography in Humans

  2010cited by this paper
• Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease.

  2010cited by this paper
• Hypermetabolism in Patients With Dementia With Lewy Bodies

  2010cited by this paper
• Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes.

  2010cited by this paper
• Cortical hypometabolism and hypoperfusion in Parkinson’s disease is extensive: probably even at early disease stages

  2010cited by this paper
• The Epidemiology of Dementia Associated with Parkinson's Disease

  2010cited by this paper
• Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models.

  2010cited by this paper
• Cerebral glucose metabolism in preclinical and prodromal Alzheimer’s disease

  2010cited by this paper
• Murine models of Alzheimer's disease and their use in developing immunotherapies.

  2010cited by this paper
• [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia.

  2010cited by this paper
• Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging.

  2009cited by this paper
• Subcortical elevation of metabolism in Parkinson's disease - A critical reappraisal in the context of global mean normalization

  2009cited by this paper
• A brain PET study in patients with narcolepsy–cataplexy

  2009cited by this paper
• Volume and iron content in basal ganglia and thalamus

  2009cited by this paper
• [Regional cerebral blood flow changes in Parkinson's disease: correlation with disease duration].

  2009cited by this paper
• Anticipatory haemodynamic signals in sensory cortex not predicted by local neuronal activity.

  2009cited by this paper
• High resolution positron emission tomography demonstrates basal ganglia dysfunction in early Parkinson's disease.

  2009cited by this paper
• Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment

  2009cited by this paper
• Artefactual subcortical hyperperfusion in PET studies normalized to global mean: Lessons from Parkinson's disease

  2009cited by this paper
• Data-driven intensity normalization of PET group comparison studies is superior to global mean normalization

  2009cited by this paper
• Neurobiology and treatment of Parkinson's disease.

  2009cited by this paper
• The neuropathological basis for depression in Parkinson's disease.

  2009cited by this paper
• SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging

  2009cited by this paper
• Abnormal regional brain function in Parkinson's disease: truth or fiction?

  2009cited by this paper
• Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features

  2009cited by this paper
• Normalization in PET group comparison studies - The importance of a valid reference region

  2008cited by this paper
• Cerebral Mitochondrial Metabolism in Early Parkinson's Disease

  2008cited by this paper
• Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease

  2008cited by this paper
• The basal ganglia in Parkinson's disease: Current concepts and unexplained observations

  2008cited by this paper
• A critical reappraisal of current staging of Lewy-related pathology in human brain

  2008cited by this paper
• Impact of chronic subthalamic high‐frequency stimulation on metabolic basal ganglia activity: a 2‐deoxyglucose uptake and cytochrome oxidase mRNA study in a macaque model of Parkinson's disease

  2007cited by this paper
• Quantification of Parkinson’s disease-related network expression with ECD SPECT

  2007cited by this paper
• Topographic Patterns of Brain Functional Impairment Progression According to Clinical Severity Staging in 116 Alzheimer Disease Patients: FDG-PET Study

  2007cited by this paper
• Cerebral glucose utilization and platelet mitochondrial complex I activity in schizophrenia: A FDG-PET study.

  2007cited by this paper
• Functional and Anatomical Magnetic Resonance Imaging in Parkinson’s Disease

  2007cited by this paper
• Relative glucose metabolic rate higher in white matter in patients with schizophrenia.

  2007cited by this paper
• Inhibition and brain work.

  2007cited by this paper
• Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner

  2007cited by this paper
• Abnormal Metabolic Network Activity in Parkinson'S Disease: Test—Retest Reproducibility

  2007cited by this paper
• Changes in network activity with the progression of Parkinson's disease.

  2007cited by this paper
• Thalamic metabolism and symptom onset in preclinical Huntington's disease.

  2007cited by this paper
• Network modulation in the treatment of Parkinson's disease.

  2006cited by this paper
• Regional cerebral blood flow in Parkinson's disease as an indicator of cognitive impairment

  2006cited by this paper
• A magnetic resonance imaging study of patients with Parkinson’s disease with mild cognitive impairment and dementia using voxel-based morphometry

  2006cited by this paper
• Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease

  2006cited by this paper
• Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease.

  2006cited by this paper
• The parkinson's complex: Parkinsonism is just the tip of the iceberg

  2006cited by this paper
• Cerebral atrophy and its relation to cognitive impairment in Parkinson disease

  2005cited by this paper
• Brain perfusion differences between Parkinson's disease and multiple system atrophy with predominant parkinsonian features.

  2005cited by this paper
• The metabolic pathology of dopa‐responsive dystonia

  2005cited by this paper
• Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease.

  2005cited by this paper
• Cerebral Blood Flow in Parkinson’s Disease, Dementia with Lewy Bodies, and Alzheimer’s Disease according to Three-Dimensional Stereotactic Surface Projection Imaging

  2005cited by this paper
• A New Approach to Spatial Covariance Modeling of Functional Brain Imaging Data: Ordinal Trend Analysis

  2005cited by this paper
• Three‐dimensional stereotactic surface projection SPECT analysis in Parkinson's disease with and without dementia

  2005cited by this paper
• Temporal Dynamics of Cortical and Subcortical Responses to Apomorphine in Parkinson Disease: An H215O PET Study

  2005cited by this paper
• Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity

  2005cited by this paper
• Relationship between regional cerebral blood flow and separate symptom clusters of major depression: a single photon emission computed tomography study using statistical parametric mapping.

  2005cited by this paper
• Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia

  2005cited by this paper
• Temporal lobe atrophy on MRI in Parkinson disease with dementia

  2005cited by this paper
• Brain FDG PET study of normal aging in Japanese: effect of atrophy correction

  2005cited by this paper
• Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study.

  2005cited by this paper
• FDG PET in the differential diagnosis of parkinsonian disorders

  2005cited by this paper
• Regional differences in cerebral blood flow and cerebral ammonia metabolism in patients with cirrhosis

  2004cited by this paper
• Statistical parametric mapping of (99m)Tc-ECD SPECT in idiopathic Parkinson's disease and multiple system atrophy with predominant parkinsonian features: correlation with clinical parameters.

  2004cited by this paper
• Executive processes in Parkinson's disease: FDG‐PET and network analysis

  2004cited by this paper
• Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice.

  2004cited by this paper
• Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies

  2004cited by this paper
• The metabolic topography of posthypoxic myoclonus

  2004cited by this paper
• Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance

  2004cited by this paper
• Mitochondrial Dysfunction and Oxidative Damage in Alzheimer's and Parkinson's Diseases and Coenzyme Q10 as a Potential Treatment

  2004cited by this paper
• Visual hallucination in Parkinson's disease with FDG PET

  2004cited by this paper
• Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.

  2004cited by this paper
• FDG-PET findings in the Wernicke-Korsakoff syndrome.

  2003cited by this paper
• The Basal Ganglia and involuntary movements: impaired inhibition of competing motor patterns.

  2003cited by this paper
• Learning networks in health and Parkinson's disease: Reproducibility and treatment effects

  2003cited by this paper
• Regional cerebral blood flow in Parkinson's disease with and without dementia

  2003cited by this paper
• Alpha-synuclein pathology affecting Bergmann glia of the cerebellum in patients with alpha-synucleinopathies.

  2003cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases.

  2003cited by this paper
• Occipital hypoperfusion in Parkinson’s disease without dementia: correlation to impaired cortical visual processing

  2003cited by this paper
• Parkinson's disease is associated with hippocampal atrophy

  2003cited by this paper
• Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model

  2003cited by this paper
• Cerebral metabolic patterns in chronic and recent-onset schizophrenia.

  2003cited by this paper
• Oxidative and Nonoxidative Metabolism of Excited Neurons and Astrocytes

  2002cited by this paper
• Statistical Parametric Mapping of 99mTc-HMPAO-SPECT Images for the Diagnosis of Alzheimer's Disease: Normalizing to Cerebellar Tracer Uptake

  2002cited by this paper
• Monosymptomatic resting tremor and Parkinson's disease: A multitracer positron emission tomographic study

  2002cited by this paper
• Primary dystonia: Is abnormal functional brain architecture linked to genotype?

  2002cited by this paper
• Tc‐99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism

  2002cited by this paper
• Twenty-four-hour non-invasive monitoring of systemic haemodynamics and cerebral blood flow velocity in healthy humans.

  2002cited by this paper
• Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease.

  2002cited by this paper
• Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease

  2002cited by this paper

• Amygdala Neurodegeneration: A Key Driver of Visual Dysfunction in Parkinson's Disease

  2025cites this paper
• Metabolic Dysregulation in Parkinson’s Disease: Non-Oxidative Phosphorylation and Its Role in Brain Energy Metabolism

  2025cites this paper
• Hemodynamic subtype profiling in tremor-dominant and akinetic–rigid Parkinson’s disease using multi-delay pseudo-continuous arterial spin labeling imaging

  2025cites this paper
• Arterial spin labeling MRI based perfusion pattern related to motor dysfunction and L-DOPA reactivity in Parkinson’s disease

  2025cites this paper
• SNMMI Procedure Standard/EANM Practice Guideline for Brain [18F]FDG PET Imaging, Version 2.0.

  2024cites this paper
• Cortical hypometabolism in Parkinson’s disease is linked to cholinergic basal forebrain atrophy

  2024cites this paper
• Seizures Triggered by Systemic Administration of 4-Aminopyridine in Rats Lead to Acute Brain Glucose Hypometabolism, as Assessed by [18F]FDG PET Neuroimaging

  2024cites this paper
• Developing a novel dual-injection FDG-PET imaging methodology to study the functional neuroanatomy of gait

  2024cites this paper
• Synaptic Density and Glucose Consumption in Patients with <scp>Lewy Body Diseases</scp> : An [ <scp> ¹¹ C </scp> ] <scp>UCB‐J</scp> and [ <scp> <sup>18

  2023cites this paper
• Pathological Correlates of Cognitive Decline in Parkinson’s Disease: From Molecules to Neural Networks

  2023cites this paper
• Auto-Classification of Parkinson’s Disease with Different Motor Subtypes Using Arterial Spin Labelling MRI Based on Machine Learning

  2023cites this paper
• NOX-induced oxidative stress is a primary trigger of major neurodegenerative disorders

  2023influential citation
• Synaptic Density and Glucose Consumption in Patients with Lewy Body Diseases: An [11C]UCB‐J and [18F]FDG PET Study

  2023cites this paper
• Impact of Visual Impairment on Vision-Related Quality of Life in Parkinson’s Disease

  2022cites this paper
• Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer’s disease: additional results from the AMBAR study

  2022cites this paper
• Neuroimmunometabolism: A New Pathological Nexus Underlying Neurodegenerative Disorders

  2022influential citation
• Voxel-Based Analysis of [18F]-FDG Brain PET in Rats Using Data-Driven Normalization

  2021cites this paper
• EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3

  2021cites this paper
• Paradoxical Cerebral Perfusion in Parkinson’s Disease Patients with Orthostatic Hypotension: A Dual-Phase 18F-Florbetaben Positron Emission Tomography Study

  2021cites this paper
• Leptin mediates protection of hydrogen sulfide against 6-hydroxydopamine-induced Parkinson's disease: Involving enhancement in Warburg effect.

  2020cites this paper
• Benefits of BCG‐induced metabolic switch from oxidative phosphorylation to aerobic glycolysis in autoimmune and nervous system diseases

  2020cites this paper
• Changes in Regional Cerebral Perfusion Over Time in Idiopathic REM Sleep Behavior Disorder

  2020cites this paper
• Intensity normalization methods in brain FDG-PET quantification

  2020cites this paper
• Blood–Brain Barrier Leakage Is Increased in Parkinson’s Disease

  2020cites this paper
• Brain-First versus Gut-First Parkinson’s Disease: A Hypothesis

  2019cites this paper
• Comparison of Count Normalization Methods for Statistical Parametric Mapping Analysis Using a Digital Brain Phantom Obtained from Fluorodeoxyglucose-positron Emission Tomography

  2019influential citation
• The Therapeutic Potential of Metformin in Neurodegenerative Diseases

  2018cites this paper
• Computational prediction of changes in brain metabolic fluxes during Parkinson’s disease from mRNA expression

  2018cites this paper
• Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway–PPAR Gamma, Energy Metabolism and Circadian Rhythms

  2018cites this paper
• Impact of Global Mean Normalization on Regional Glucose Metabolism in the Human Brain

  2018cites this paper
• Early perfusion and dopamine transporter imaging using 18F-FP-CIT PET/CT in patients with parkinsonism.

  2018cites this paper
• Structural and physiological neurovascular changes in idiopathic Parkinson’s disease and its clinical phenotypes

  2017influential citation
• The vicious circle of hypometabolism in neurodegenerative diseases: Ways and mechanisms of metabolic correction

  2017cites this paper
• Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots

  2017cites this paper
• Impaired synaptic function is linked to cognition in Parkinson's disease

  2017cites this paper
• Evaluation of an optimized [18F]fluoro‐deoxy‐glucose positron emission tomography voxel‐wise method to early support differential diagnosis in atypical Parkinsonian disorders

  2017cites this paper
• Chapter 4 Computational prediction of changes in brain metabolic fluxes from mRNA expression in Parkinson’s disease

  2016cites this paper
• Loss of ATP13A2 impairs glycolytic function in Kufor-Rakeb syndrome patient-derived cell models.

  2016cites this paper
• Color-Coded Digital Subtraction Angiography in the Management of a Rare Case of Middle Cerebral Artery Pure Arterial Malformation

  2014cites this paper
• PENTOSEPHOSPHATE PATHWAY DISRUPTION IN THE PATHOGENESIS

  2014cites this paper
• Pentose-phosphate pathway disruption in the pathogenesis of Parkinson’s disease

  2014cites this paper
• Differential Diagnosis Between Neurodegenerative Dementia Disorders and Parkinson’s Disease Using 99mTc-HMPAO SPECT

  2014cites this paper
• Review - Part of the Special Issue: Alzheimer's Disease - Amyloid, Tau and Beyond Mitochondrial respiration as a target for neuroprotection and cognitive enhancement

  2014cites this paper
• Differential Diagnosis Between Neurodegenerative Dementia Disorders and Parkinson ’ s Disease Using 99 mTc-HMPAO SPECT

  2014cites this paper
• Nicotinic α4β2 acetylcholine receptors and cognitive function in Parkinson's disease

  2014cites this paper
• Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease☆

  2014cites this paper
• Études de la subthalamotomie comme traitement des dyskinésies chez le primate parkinsonien

  2013cites this paper